| Document |
Document Title |
|
WO/2021/011692A1 |
Provided herein are 5-fluorouracil derived cyclic deoxyribonucleotide compounds, their preparation and their uses, such as treating liver diseases or various types of cancer.
|
|
WO/2021/004940A1 |
The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is beta-D-galactopyranose, and these compounds are high affinity galectin-1 and/or 3 inhibitors for use in treatment of inflammation; ...
|
|
WO/2021/007283A1 |
Described herein are methods of treating RNA virus infections with a therapeutic combination of an antiviral nucleobase compound and a de novo nucleotide biosynthesis inhibitor (DNNBi). An aspect of the invention is a method for the trea...
|
|
WO/2021/001528A1 |
The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-1 and/or galectin 3 inhibitors for use in treatment of inflamm...
|
|
WO/2021/000380A1 |
The present disclosure relates to the technical field of nucleic acid medicines, in particular to a modified nucleoside, a nucleotide and a modified nucleic acid polymer, as well as a preparation method therefor and an application thereo...
|
|
WO/2021/001329A1 |
The invention relates to a new process for the preparation of high water affinity type products with controlled humidity via spray drying in a suitable spray drying equipment applying specific spray drying parameters.
|
|
WO/2021/001538A1 |
The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-3 inhibitors for use in treatment of inflammation; Inflammatio...
|
|
WO/2020/260351A1 |
The present invention relates to a process for preparing a compound of formula (I), wherein said process is suitable for large scale synthesis.
|
|
WO/2020/257429A1 |
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
|
|
WO/2020/253872A1 |
2-Benzylidene hydrazinoadenosine compounds having A2A adenosine receptor agonistic activity, represented by a general formula (I) and pharmaceutical compositions containing the same. The compounds and compositions may act as A2A adenosin...
|
|
WO/2020/256084A1 |
A crystal of a compound represented by formula 5. In formula 5, R1 represents a hydroxyl protecting group, and R2 represents a leaving group.
|
|
WO/2020/255978A1 |
[Problem] To provide a novel phosphate ester compound having a pyrrolopyrimidine skeleton or a pharmaceutically acceptable salt thereof which has excellent antitumor effects, and a method for preventing and/or treating a tumor that is us...
|
|
WO/2020/253866A1 |
The present invention relates to a compound represented by formula I or a pharmaceutically acceptable salt, stereoisomeride, pharmaceutically acceptable hydrate or solvate, or pharmaceutically acceptable ester thereof, wherein R is selec...
|
|
WO/2020/253867A1 |
The present application provides a small-molecule compound, represented by general formula (I), having A2A adenosine receptor antagonistic activity and a pharmaceutical composition containing same. The compound and composition can be use...
|
|
WO/2020/253870A1 |
The present disclosure provides 6-hydrazinoadenosine having A2A adenosine receptor agonistic activity represented by general formula (I) and a derivative thereof, and a pharmaceutical composition containing same. The compound and composi...
|
|
WO/2020/257283A1 |
The disclosure provides nicotinamide riboside (NR), the reduced form of NR (NRH), nicotinic acid riboside (NAR), the reduced form of NAR (NARH), derivatives thereof, compositions thereof and uses thereof. The NR and NAR derivatives have ...
|
|
WO/2020/255979A1 |
[Problem] To provide: a novel carbonate compound of nucleotides which has a pyrrolopyrimidine skeleton and exhibits an excellent antitumor effect, or a pharmaceutically acceptable salt thereof; and a method for preventing and/or treating...
|
|
WO/2020/248068A1 |
The present application provides a synthetic method for production of 3-azido-3-deoxy-D-galactopyranose. Also provided are methods of using the 3-azido-3-deoxy-D-galactopyranose in the manufacture of galactoside galectin antagonists, suc...
|
|
WO/2020/252380A2 |
The present disclosure is concerned with 2,4,7-substituted-7-deaza-2'-deoxy-2'- fluoroarabinosyl nucleoside and nucleotide prodrugs that are capable of inhibiting viral infections and methods of treating viral infections such as, for exa...
|
|
WO/2020/245191A1 |
The present invention provides compounds and compositions containing reduced nicotinamide riboside for use in methods of prevention and/or treatment of skeletal muscle disease and/or conditions. In one embodiment of the invention, said c...
|
|
WO/2020/247818A1 |
Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a disease which utilize...
|
|
WO/2020/246616A1 |
[Problem] To provide a novel fluorescent probe. [Solution] The compound represented by general formula (I), or a salt thereof.
|
|
WO/2020/247546A1 |
The disclosure provides adenosine analogs for the treatment of disease such as pain and inflammatory conditions.
|
|
WO/2020/247782A1 |
Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize ...
|
|
WO/2020/235658A1 |
Provided are a multi-fluorous blockmer capable of reducing the purification burden using a readily available fluorous tag, and an oligonucleotide synthesis method using the same. A multi-fluorous blockmer represented by the formula is sy...
|
|
WO/2020/227132A1 |
Provided herein are prodrugs of 5-fluorodeoxyuridine monophosphate compounds, compositions thereof, methods of their preparation, and their use in treating cancers. In another aspect, provided herein is a pharmaceutical composition compr...
|
|
WO/2020/227421A1 |
Provided herein are compounds of Formula (I), Formula (II) and/or Formula (III), or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutical...
|
|
WO/2020/223530A1 |
Provided herein are phosphorylated gemcitabine derivative prodrug compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of cancer.
|
|
WO/2020/221209A1 |
A CD73 inhibitor having the structure represented by formula (I), a preparation method therefor and an application thereof. The series of compounds can be widely applied in the preparation of drugs for treating cancers or tumors that are...
|
|
WO/2020/219417A1 |
Compounds, compositions, and methods for treating and/or preventing at least one disease, disorder, and/or condition associated with E-selectin, galectin-3, and/or CXCR4 chemokine receptor activity are disclosed herein. For example, mult...
|
|
WO/2020/219464A1 |
Provided herein are cyclic phosphate compounds, their preparation and their uses, such as treating liver diseases or conditions or a disease or condition in which the physiological or pathogenic pathways involve the liver.
|
|
WO/2020/216326A1 |
The disclosure provides compounds of formula (I), wherein R1, R2, R5, R6, R7, L1, L2, W1, W2, and Z1 are as defined herein, and compositions comprising same, and methods related to activating alpha-kinase 1 (ALPK1) for modulating an immu...
|
|
WO/2020/216646A1 |
Disclosed herein are nucleoside derivatives, cytidine derivatives and Gemcitabine derivatives and methods of forming nucleoside derivatives, cytidine derivatives and Gemcitabine derivatives.
|
|
WO/2020/214589A1 |
Modified nucleotides, such as α-phosphoseleno-nucleotides (dNTPαSe and NTPαSe), can be incorporated into nucleic acids by enzymatic processes in a similar manner as naturally occurring nucleotides. Altering the properties of modified ...
|
|
WO/2020/211672A1 |
The present disclosure relates generally to compounds that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions. Compositions containing the compounds of the present disclosure are also provided.
|
|
WO/2020/210970A1 |
The present disclosure relates generally to imidazotriazine derivatives that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions. Compositions containing the compounds of the present disclosure are al...
|
|
WO/2020/212301A1 |
The present invention relates to an optimized method for preparing a P(V) monomer of formula (IIIa) or (IIIb) from a nucleoside using DBU as a base at about 0.8 equivalent to nucleoside.
|
|
WO/2020/176741A9 |
Provided are methods of treating multiple sclerosis, which comprises administering to a patient a therapeutically effective amount of DNA methylation blocker. Also provided are method of retarding development of multiple sclerosis by adm...
|
|
WO/2020/203896A1 |
The present invention addresses the problem of providing a new artificial nucleic acid, a production method therefor, and a use thereof. The problem can be solved by an artificial nucleic acid having a unit derived from a compound repres...
|
|
WO/2020/204022A1 |
Provided is a method for manufacturing a compound represented by formula (III) by using, as a material, a compound represented by formula (I).
|
|
WO/2020/201751A1 |
The present invention relates to salts of triphosphate phosphoramidates which are useful in the treatment of cancer.
|
|
WO/2020/193765A1 |
Embodiments of the present disclosure relate to nucleotides labeled with photoswitchable compounds. Also provided herein are methods and kits of using these labeled nucleotides for sequencing applications.
|
|
WO/2020/198266A1 |
The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
|
|
WO/2020/197882A1 |
The invention relates to compounds and compositions for modulation of nicotinamide adenine dinucleotide (NAD+). The invention also relates to methods of making such compounds and compositions. The invention relates to pharmaceutical comp...
|
|
WO/2020/190073A1 |
The present invention relates to a pharmaceutical composition for the prophylaxis or treatment of cancer comprising a novel azolopyrimidine heterocyclic compound as an active ingredient, and the pharmaceutical composition for the prophyl...
|
|
WO/2020/190703A1 |
The present application provides methods for treating wounds by administering a combination of nicotinamide riboside and pterostilbene. The compositions can be administered orally or as a topical formulation.
|
|
WO/2020/188288A1 |
The present invention relates to compounds of Formula (I) for use in the treatment of nervous system disorders and pain, wherein Formula (I) is: formula(I) or a pharmaceutically acceptable salt or isomer thereof, wherein R is defined her...
|
|
WO/2020/191252A1 |
Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and signi...
|
|
WO/2020/186588A1 |
Disclosed is a crystal form A of a 2'-fluoro-4'-substituted nucleoside analog I, wherein same falls within the field of pharmaceutical chemistry. The crystal form A has the following structure: (I). The CuKα-XRPD pattern of the crystal ...
|
|
WO/2020/184677A1 |
The present invention addresses the problem of providing an anti-hepatitis B virus agent and a prophylactic or therapeutic agent for hepatitis B virus-associated diseases, containing a nucleic acid analog as an active ingredient. The pro...
|
